中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 10
Oct.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(10): 2307-2320

Chinese expert consensus on clinical management of hepatopathy－related thrombocytopenia

DOI: 10.3969/j.issn.1001-5256.2023.10.007
  • Received Date: 2023-09-20
  • Published Date: 2023-10-30
    Abstract
  • Hepatopathy－related thrombocytopenia refers to a decrease in platelet count caused by liver disease or its treatment， and the incidence rate of this disease is associated with the course and severity of liver disease. The direct effect of thrombocytopenia on the clinical outcome of patients with liver disease is an increased risk of bleeding， and its indirect effect involves delay or discontinuation of treatment due to the potential risk of bleeding. The pathophysiological mechanisms of hepatopathy－related thrombocytopenia involve reduced platelet production， abnormal platelet distribution， and increased destruction or consumption. Current treatment strategies aiming at different mechanisms include thrombopoietic agents， surgery， immunosuppressants， and platelet transfusion， but their clinical application needs further standardization. In order to improve the clinical management of hepatopathy－related thrombocytopenia in China in terms of diagnosis， typing， and rational selection of treatment regimens， National Clinical Research Center for Infectious Diseases organized experts to discuss and develop these consensus statements with reference to the latest evidence of evidence－based medicine in this field.

     

    • FullText(HTML)
  • loading
    • References(72)
  • [1]
    GANGIREDDY VGR, KANNEGANTI PC, SRIDHAR S, et al. Management of thrombocytopenia in advanced liver disease[J]. Can J Gastroenterol Hepatol, 2014, 28( 10): 558－ 564. DOI: 10.1155/2014/532191.
    [2]
    HUANG CH, CHANG JJ, WU YY, et al. Different impacts of common risk factors associated with thrombocytopenia in patients with hepatitis B virus and hepatitis C virus infection[J]. Biomed J, 2022, 45( 5): 788－ 797. DOI: 10.1016/j.bj.2021.09.001.
    [3]
    LI QJ, HE MK, CHEN HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III trial[J]. J Clin Oncol, 2022, 40( 2): 150－ 160. DOI: 10.1200/JCO.21.00608.
    [4]
    KUDO M, UESHIMA K, YOKOSUKA O, et al. Sorafenib plus low－dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma(SILIUS): A randomised, open label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2018, 3( 6): 424－ 432. DOI: 10.1016/S2468－1253(18)30078－5.
    [5]
    PECK－RADOSAVLJEVIC M. Thrombocytopenia in chronic liver disease[J]. Liver Int, 2017, 37( 6): 778－ 793. DOI: 10.1111/liv.13317.
    [6]
    GALLO P, TERRACCIANI F, DI PASQUALE G, et al. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures[J]. World J Gastroenterol, 2022, 28( 30): 4061－ 4074. DOI: 10.3748/wjg.v28.i30.4061.
    [7]
    ADINOLFI LE, GIORDANO MG, ANDREANA A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis[J]. Br J Haematol, 2001, 113( 3): 590－ 595. DOI: 10.1046/j.1365－2141.2001.02824.x.
    [8]
    PEREIRA J, ACCATINO L, ALFARO J, et al. Platelet autoantibodies in patients with chronic liver disease[J]. Am J Hematol, 1995, 50( 3): 173－ 178. DOI: 10.1002/ajh.2830500305.
    [9]
    XIAO H, WANG L. Mechanisms of throm bocytopenia in liver cirrhosis[J]. J Pract Hepatol, 2019, 22( 4): 462－ 465. DOI: 10.3969/j.issn.1672－5069.2019.04.003.

    肖函, 王利. 肝硬化血小板减少的病理生理发生机制[J]. 实用肝脏病杂志, 2019, 22( 4): 462－ 465. DOI: 10.3969/j.issn.1672－5069.2019.04.003.
    [10]
    MITCHELL O, FELDMAN DM, DIAKOW M, et al. The pathophysiology of thrombocytopenia in chronic liver disease[J]. Hepat Med, 2016, 8: 39－ 50. DOI: 10.2147/HMER.S74612.
    [11]
    KANEKO J, SUGAWARA Y, MATSUI Y, et al. Normal splenic volume in adults by computed tomography[J]. Hepato－gastroenterology, 2002, 49( 48): 1726－ 1727.
    [12]
    Thrombosis and Hemostasis Group, Society of Hematology, Chinese Medical Association. Chinese guideline on the diagnosis and management of adult primary immune thrombocytopenia(version 2020)[J]. Chin J Hematol, 2020, 41( 8): 617－ 623. DOI: 10.3760/cma.j.issn.0253－2727.2020.08.001

    中华医学会血液学分会血栓与止血学组, 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志, 2020, 41( 8): 617－ 623. DOI: 10.3760/cma.j.issn.0253－2727.2020.08.001
    [13]
    Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 42－ 49. DOI: 10.3760/cma.j.cn112138－20211112－00796.

    中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 42－ 49. DOI: 10.3760/cma.j.cn112138－20211112－00796.
    [14]
    General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer(2022 edition)[J]. J Clin Hepatol, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009.

    国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38( 2): 288－ 303. DOI: 10.3969/j.issn.1001－5256.2022.02.009.
    [15]
    AL－SAMKARI H, SOFF GA. Clinical challenges and promising therapies for chemotherapy－induced thrombocytopenia[J]. Expert Rev Hematol, 2021, 14( 5): 437－ 448. DOI: 10.1080/17474086.2021.1924053.
    [16]
    Red Cell Diseases(Anemia) Group, Society of Hematology, Chinese Medical Association. Diagnosis and treatment of aplastic anemia China guide(2022 edition)[J]. Chin J Hematol, 2022( 11): 881－ 888.

    中华医学会血液学分会红细胞疾病(贫血)学组, 再生障碍性贫血诊断与治疗中国指南(2022年版)[J]. 中华血液学杂志, 2022( 11): 881－ 888.
    [17]
    POCKETT RD, CASTELLANO D, MCEWAN P, et al. The hospital burden of disease associated with bone metastases and skeletal－related events in patients with breast cancer, lung cancer, or prostate cancer in Spain[J]. Eur J Cancer Care, 2010, 19( 6): 755－ 760. DOI: 10.1111/j.1365－2354.2009.01135.x.
    [18]
    FRANCHINI M, VENERI D, LIPPI G. Thrombocytopenia and infections[J]. Expert Rev Hematol, 2017, 10( 1): 99－ 106. DOI: 10.1080/17474086.2017.1271319.
    [19]
    KLEIN A, MOLAD Y. Hematological manifestations among patients with rheumatic diseases[J]. Acta Haematol, 2021, 144( 4): 403－ 412. DOI: 10.1159/000511759.
    [20]
    LI LP, YING H. Etiology and differential diagnosis of thrombocytopenia in pregnancy[J]. Chin J Pract Gynecol Obstet, 2022, 38( 12): 1166－ 1170.

    李莉平, 应豪. 妊娠期血小板减少的原因与鉴别诊断[J]. 中国实用妇科与产科杂志, 2022, 38( 12): 1166－ 1170.
    [21]
    HE YY. Application value of systematic analysis of hemolytic etiology in diagnosis and differentiation of hereditary hemolytic anemia[J]. Mod Med J China, 2018, 20( 4): 55－ 57.

    何永艳. 溶血病因系统分析在遗传性溶血性贫血诊断和鉴别中的应用价值[J]. 中国现代医药杂志, 2018, 20( 4): 55－ 57.
    [22]
    IKEZOE T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies[J]. Int J Hematol, 2021, 113( 1): 34－ 44. DOI: 10.1007/s12185－020－02992－w.
    [23]
    SALAMA A. Autoimmune thrombocytopenia complicated by EDTA－and/or citrate－dependent pseudothrombocytopenia[J]. Transfus Med Hemother, 2015, 42( 5): 345－ 348. DOI: 10.1159/000437220.
    [24]
    LI Q, CHEN L, YU XH. Differentiation of bone marrow cell morphology of thrombocytopenia in chronic liver disease and primary immune thrombocytopenia[J]. Chin J Pract Med, 2022, 49( 8): 10－ 12. DOI: 10.3760/cma.j.cn115689－20220122－00349.

    李清, 陈雷, 余晓红. 慢性肝病血小板减少症与原发免疫性血小板减少症的骨髓细胞形态的鉴别[J]. 中国实用医刊, 2022, 49( 8): 10－ 12. DOI: 10.3760/cma.j.cn115689－20220122－00349.
    [25]
    BIOLATO M, VITALE F, GALASSO T, et al. Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines[J]. World J Gastrointest Surg, 2023, 15( 2): 127－ 141. DOI: 10.4240/wjgs.v15.i2.127.
    [26]
    ALVARO D, CAPORASO N, GIANNINI EG, et al. Procedure－related bleeding risk in patients with cirrhosis and severe thrombocytopenia[J]. Eur J Clin Invest, 2021, 51( 6): e13508. DOI: 10.1111/eci.13508.
    [27]
    Writing Group of The Xiangya Expert Consensus on Liver Needle Biopsy. Writing group of the xiangya expert consensus on liver needle biopsy[J]. Chin J Gen Surg, 2021, 30( 1): 1－ 8. DOI: 10.7659/j.issn.1005－6947.2021.01.001.

    肝脏穿刺活检湘雅专家共识编写组. 肝脏穿刺活检湘雅专家共识[J]. 中国普通外科杂志, 2021, 30( 1): 1－ 8. DOI: 10.7659/j.issn.1005－6947.2021.01.001.
    [28]
    Clinical Guidelines Committee of Chinese Interventionalists College. Chinese clinical practice guidelines for transarterial chemoembolization of hepatocellular carcinoma[J]. Chin J Intern Med, 2021, 60( 7): 599－ 614. DOI: 10.3760/cma.j.cn112137－20210425－00991.

    中国医师协会介入医师分会临床诊疗指南专委会. 中国肝细胞癌经动脉化疗栓塞(TACE)治疗临床实践指南(2021年版)[J]. 中华内科杂志, 2021, 60( 7): 599－ 614. DOI: 10.3760/cma.j.cn112137－20210425－00991.
    [29]
    WANG GZ, HE XH, WANG Y, et al. Clinical practice guideline for image－guided multimode tumour ablation therapy in hepatic malignant tumours[J]. Curr Oncol, 2019, 26( 5): e658－e664. DOI: 10.3747/co.26.5423.
    [30]
    Chinese Society of Liver Cancer, China Anti－Cancer Association. Chinese expert consensus on hepatic arterial infusion chemotherapy for hepatocellular carcinoma(2021 edition)[J]. Chin J Dig Surg, 2021, 20( 7): 754－ 759. DOI: 10.3760/cma.j.cn115610－20210618－00288.

    中国抗癌协会肝癌专业委员会. 肝动脉灌注化疗治疗肝细胞癌中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20( 7): 754－ 759. DOI: 10.3760/cma.j.cn115610－20210618－00288.
    [31]
    TRIPATHI D, STANLEY AJ, HAYES PC, et al. Transjugular intrahepatic portosystemic stent－shunt in the management of portal hypertension[J]. Gut, 2020, 69( 7): 1173－ 1192. DOI: 10.1136/gutjnl－2019－320221.
    [32]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, et al. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.
    [33]
    Chinese Chapter of The International Hepato－Pancreato－Biliary Association; Group of Liver Surgery, Surgical Society of Chinese Medical Association; Expert Committee on Liver Cancer, Chinese Society of Clinical Oncology. Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)[J]. Chin J Hepatol, 2021, 29( 7): 636－ 647. DOI: 10.3760/cma.j.cn501113－20210604－00261.

    国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会(CSCO)肝癌专家委员会. 基于免疫节点抑制剂的肝细胞癌免疫联合治疗多学科中国专家共识(2021版)[J]. 中华肝脏病杂志, 2021, 29( 7): 636－ 647. DOI: 10.3760/cma.j.cn501113－20210604－00261.
    [34]
    Liver Cancer Committee of Chinese Medical Doctor Association. China expert consensus on clinical application of molecular targeted drugs for hepatocellular carcinoma(2020 edition)[J]. Natl Med J China, 2021, 101( 28): 2185－ 2194. DOI: 10.3760/cma.j.cn112137－20210329－00760.

    中国医师协会肝癌专业委员会. 肝细胞癌分子靶向药物临床应用中国专家共识(2020版)[J]. 中华医学杂志, 2021, 101( 28): 2185－ 2194. DOI: 10.3760/cma.j.cn112137－20210329－00760.
    [35]
    Cuidelines Working Committee of Chinese Society of Clinical Oncology. Chinese society of clinical oncology(CSCO). Guidelines of Chinese society of clinical oncology(CSCO) cancer therapy induced thrombocytopenia[M]. Beijing: People’s Medical Publishing House, 2022.

    中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)肿瘤治疗所致血小板减少症诊疗指南－2022[M]. 北京: 人民卫生出版社, 2022.
    [36]
    Nuclear Medicine Committee, Chinese Society of Clinical Oncology; Beijing Nuclear Medicine Quality Control and Improvement Center. Chinese expert consensus on selective internal radiation therapy with yttrium－90 for primary and metastatic hepatocellular carcinoma[J]. Chin J Hepatol, 2021, 29( 7): 648－ 658. DOI: 10.3760/cma.j.cn501113－20210302－00103.

    中国临床肿瘤学会核医学专家委员会, 北京市核医学质量控制和改进中心. 钇－90( 90Y)微球选择性内放射治疗原发性和转移性肝癌的中国专家共识[J]. 中华肝脏病杂志, 2021, 29( 7): 648－ 658. DOI: 10.3760/cma.j.cn501113－20210302－00103.
    [37]
    TERRAULT N, CHEN YC, IZUMI N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia[J]. Gastroenterology, 2018, 155( 3): 705－ 718. DOI: 10.1053/j.gastro.2018.05.025.
    [38]
    HUANG A, CHEN JF, WU JZ, et al. Effectiveness and safety of avatrombopag in liver cancer patients with severe thrombocytopenia: Real－world data and challenges[J]. J Oncol, 2022, 2022: 9138195. DOI: 10.1155/2022/9138195.
    [39]
    LI RX, YANG H, SONG YH, et al. Avatrombopag combined with intensive immune inhibition in the treatment of severe hepatitis－associated aplastic anemia: Report of two cases[J]. Chin J Pract Intern Med, 2021, 41( 12): 1086－ 1088. DOI: 10.19538/j.nk2021120120.

    李瑞鑫, 杨慧, 宋玉华, 等. 阿伐曲泊帕联合强化免疫抑制治疗重型肝炎相关性再生障碍性贫血2例报告[J]. 中国实用内科杂志, 2021, 41( 12): 1086－ 1088. DOI: 10.19538/j.nk2021120120.
    [40]
    LI RX, LIU ZY, ZHOU JT, et al. Avatrombopag in treatment of lenvatinib－related severe aplastic anemia: Report of one case and review of literature[J]. J Leuk Lymphoma, 2021, 30( 10): 618－ 620. DOI: 10.3760/cma.j.cn115356－20210409－00078.

    李瑞鑫, 刘正媛, 周炯涛, 等. 阿伐曲泊帕治疗仑伐替尼相关重型再生障碍性贫血一例并文献复习[J]. 白血病·淋巴瘤, 2021, 30( 10): 618－ 620. DOI: 10.3760/cma.j.cn115356－20210409－00078.
    [41]
    HIDAKA H, KUROSAKI M, TANAKA H, et al. Lusutrombopag reduces need for platelet transfusion in patients with thrombocytopenia undergoing invasive procedures[J]. Clin Gastroenterol Hepatol, 2019, 17( 6): 1192－ 1200. DOI: 10.1016/j.cgh.2018.11.047.
    [42]
    DING ZB, WU H, ZENG YY, et al. Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures[J]. Hepatol Int, 2023, 17( 1): 180－ 189. DOI: 10.1007/s12072－022－10421－9.
    [43]
    KATSUBE T, WAJIMA T, FUKUHARA T, et al. Effects of food and calcium carbonate on the pharmacokinetics of lusutrombopag, a novel thrombopoietin receptor agonist[J]. Clin Ther, 2019, 41( 9): 1747－ 1754.e 2. DOI: 10.1016/j.clinthera.2019.06.004.
    [44]
    AFDHAL NH, GIANNINI EG, TAYYAB G, et al. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia[J]. N Engl J Med, 2012, 367( 8): 716－ 724. DOI: 10.1056/NEJMoa1110709.
    [45]
    HERMANN E, FERDJALLAH A. Eltrombopag－induced metabolic acidosis and hepatic encephalopathy in pediatric ITP[J]. J Pediatr Hematol Oncol, 2022, 44( 2): e453－e455. DOI: 10.1097/MPH.0000000000002300.
    [46]
    MOUSSA MM, MOWAFY N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis[J]. J Gastroenterol Hepatol, 2013, 28( 2): 335－ 341. DOI: 10.1111/j.1440－1746.2012.07246.x.
    [47]
    FENG R, LIU Y, ZHU XL, et al. Recombinant human thrombopoietin increases platelet count in severe thrombocytopenic patients with hepatitis B－related cirrhosis: Multicentre real－world observational study[J]. J Viral Hepat, 2022, 29( 5): 306－ 316. DOI: 10.1111/jvh.13655.
    [48]
    DING JN, FENG TT, SUN W, et al. Recombinant human thrombopoietin treatment in patients with chronic liver disease－related thrombocytopenia undergoing invasive procedures: A retrospective study[J]. World J Gastrointest Surg, 2022, 14( 11): 1260－ 1271. DOI: 10.4240/wjgs.v14.i11.1260.
    [49]
    LIU BW, XIANG HL, LIANG J, et al. Comparison of efficacy of recombinant human interleukin－11 and recombinant human thrombopoietin in treating thrombocytopenia with hypersplenism in cirrhotic patients[J]. World Chin J Dig, 2016, 24( 34): 4608－ 4614. DOI: 10.11569/wcjd.v24.i34.4608.

    刘保文, 向慧玲, 梁静, 等. 重组人白介素－11及重组人血小板生成素在治疗肝硬化脾功能亢进所致血小板减少的疗效对比[J]. 世界华人消化杂志, 2016, 24( 34): 4608－ 4614. DOI: 10.11569/wcjd.v24.i34.4608.
    [50]
    KUTER DJ. Treatment of chemotherapy－induced thrombocytopenia in patients with non－hematologic malignancies[J]. Haematologica, 2022, 107( 6): 1243－ 1263. DOI: 10.3324/haematol.2021.279512.
    [51]
    Anti－Lymphoma Alliance in CSCO, Anti－Leukemia Alliance in CSCO, ASMC Group in CSCO, et al. China expert consensus on clinical application of recombinant human interleukin－11 in prevention and treatment of thrombocytopenia(2021 edition)[J]. Chin Clin Oncol, 2020, 25( 12): 1129－ 1137. DOI: 10.3969/j.issn.1009－0460.2020.12.014.

    中国临床肿瘤学会抗淋巴瘤联盟, 中国临床肿瘤学会抗白血病联盟, 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会, 等. 重组人白介素－11防治血小板减少症临床应用中国专家共识(2021年版)[J]. 临床肿瘤学杂志, 2020, 25( 12): 1129－ 1137. DOI: 10.3969/j.issn.1009－0460.2020.12.014.
    [52]
    LIU L, LIU Y, GAO FY, et al. Clinical features of chronic liver disease with autoimmune blood diseases and the clinical effect of glucocorticoid[J]. J Clin Hepatol, 2021, 37( 8): 1878－ 1882. DOI: 10.3969/j.issn.1001－5256.2021.08.025.

    刘龙, 刘遥, 高方媛, 等. 慢性肝病合并自身免疫性血液系统疾病的临床特征及应用糖皮质激素治疗效果分析[J]. 临床肝胆病杂志, 2021, 37( 8): 1878－ 1882. DOI: 10.3969/j.issn.1001－5256.2021.08.025.
    [53]
    WU YY, LI HY, ZHANG TS, et al. Splanchnic vein thrombosis in liver cirrhosis after splenectomy or splenic artery embolization: A systematic review and meta－analysis[J]. Adv Ther, 2021, 38( 4): 1904－ 1930. DOI: 10.1007/s12325－021－01652－7.
    [54]
    ZHAO P, LI T, XIE JL, et al. Value of early anticoagulant intervention in cirrhotic patients with portal hypertension after transjugular intrahepatic portosystemic stent shunt combined with PSE[J]. J Pract Hepatol, 2020, 23( 1): 82－ 85. DOI: 10.3969/j.issn.1672－5069.2020.01.023.

    赵平, 黎涛, 谢吉良, 等. 早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨[J]. 实用肝脏病杂志, 2020, 23( 1): 82－ 85. DOI: 10.3969/j.issn.1672－5069.2020.01.023.
    [55]
    FENG K, MA K, LIU Q, et al. Randomized clinical trial of splenic radiofrequency ablation versus splenectomy for severe hypersplenism[J]. Br J Surg, 2011, 98( 3): 354－ 361. DOI: 10.1002/bjs.7367.
    [56]
    OGATA T, OKUDA K, SATO T, et al. Long－term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia[J]. Kurume Med J, 2013, 60( 2): 37－ 45. DOI: 10.2739/kurumemedj.ms62010.
    [57]
    SHI XB, FENG JK, WANG JH, et al. Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta－analysis[J]. Ann Transl Med, 2021, 9( 8): 641. DOI: 10.21037/atm－20－6748.
    [58]
    CHU HB, HAN W, WANG L, et al. Long－term efficacy of subtotal splenectomy due to portal hypertension in cirrhotic patients[J]. BMC Surg, 2015, 15: 89. DOI: 10.1186/s12893－015－0077－2.
    [59]
    LIU X, QI XS, LI HY, et al. Prevalence of portal or splenic vein thrombosis in cirrhotic patients after splenectomy: A systematic review and meta－analysis of observational studies[J]. Int J Clin Exp Med, 2016, 9( 4): 7534－ 7547.
    [60]
    TRIPODI A, PRIMIGNANI M, CHANTARANGKUL V, et al. Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion[J]. Liver Int, 2013, 33( 3): 362－ 367. DOI: 10.1111/liv.12038.
    [61]
    WANG SY, ZHOU WH, LI XY, et al. Analysis of platelet transfusion in liver disease patient[J]. J Clin Transfus Lab Med, 2017, 19( 4): 328－ 331. DOI: 10.3969/j.issn.1671－2587.2017.04.005.

    王淑英, 周文辉, 李新颖, 等. 肝病患者血小板输注情况调查分析[J]. 临床输血与检验, 2017, 19( 4): 328－ 331. DOI: 10.3969/j.issn.1671－2587.2017.04.005.
    [62]
    FURUICHI Y, TAKEUCHI H, YOSHIMASU Y, et al. Thrombopoietin receptor agonist is more effective than platelet transfusion for chronic liver disease with thrombocytopenia, shown by propensity score matching[J]. Hepatol Res, 2020, 50( 9): 1062－ 1070. DOI: 10.1111/hepr.13530.
    [63]
    WEN LL, YU ZL, LIANG HL, et al. The main recommendation and enlightenment of application guidelines for platelet transfusion from British Society for Haematology[J]. Chin J Blood Transfus, 2018, 31( 4): 440－ 444. DOI: 10.13303/j.cjbt.issn.1004－549x.2018.04.032.

    温丽玲, 余卓丽, 梁惠兰, 等. 英国血小板输注应用指南主要推荐及其启示[J]. 中国输血杂志, 2018, 31( 4): 440－ 444. DOI: 10.13303/j.cjbt.issn.1004－549x.2018.04.032.
    [64]
    ZHU H, WANG SY, ZHU JH, et al. Efficacy and safety of transcatheter arterial chemoembolization combined with ginsenosides in hepatocellular carcinoma treatment[J]. Phytomedicine, 2021, 91: 153700. DOI: 10.1016/j.phymed.2021.153700.
    [65]
    NORONHA FERREIRA C, MARINHO RT, CORTEZ－PINTO H, et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study[J]. Liver Int, 2019, 39( 8): 1459－ 1467. DOI: 10.1111/liv.14121.
    [66]
    QI XS, DE STEFANO V, LI HY, et al. Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: A systematic review and meta－analysis of observational studies[J]. Eur J Intern Med, 2015, 26( 1): 23－ 29. DOI: 10.1016/j.ejim.2014.12.002.
    [67]
    LOFFREDO L, PASTORI D, FARCOMENI A, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: A systematic review and meta－analysis[J]. Gastroenterology, 2017, 153( 2): 480－ 487.e 1. DOI: 10.1053/j.gastro.2017.04.042.
    [68]
    ZHOU T, SUN X, ZHOU T, et al. Efficacy and safety of nadroparin calcium－warfarin sequential anticoagulation in portal vein thrombosis in cirrhotic patients: A randomized controlled trial[J]. Clin Transl Gastroenterol, 2020, 11( 9): e00228. DOI: 10.14309/ctg.0000000000000228.
    [69]
    Hepatobiliary Disease Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. Consensus for management of portal vein thrombosis in liver cirrhosis(2020,Shanghai)[J]. J Clin Hepatol, 2020, 36( 12): 2667－ 2674. DOI: 10.3969/j.issn.1001－5256.2020.12.007.

    中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年, 上海)[J]. 临床肝胆病杂志, 2020, 36( 12): 2667－ 2674. DOI: 10.3969/j.issn.1001－5256.2020.12.007.
    [70]
    DECOUSUS H, TAPSON VF, BERGMANN JF, et al. Factors at admission associated with bleeding risk in medical patients: Findings from the IMPROVE investigators[J]. Chest, 2011, 139( 1): 69－ 79. DOI: 10.1378/chest.09－3081.
    [71]
    KHANAL N, BOCIEK RG, CHEN BJ, et al. Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia[J]. Am J Hematol, 2016, 91( 11): E468－E472. DOI: 10.1002/ajh.24526.
    [72]
    FALANGA A, LEADER A, AMBAGLIO C, et al. EHA guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer[J]. HemaSphere, 2022, 6( 8): e750. DOI: 10.1097/HS9.0000000000000750.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(9)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1258) PDF downloads(526) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return